Determine the necessary mass, volume, or concentration for preparing a solution.
This is a demo store. No orders will be fulfilled.
| SKU | Size | Availability |
Price | Qty |
|---|---|---|---|---|
|
G650392-1mg
|
1mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$217.90
|
|
|
G650392-5mg
|
5mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$456.90
|
|
|
G650392-10mg
|
10mg |
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
|
$816.90
|
|
| Synonyms | A898918 | BDBM50079446 | glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine | Glycyl-arginyl-glycyl-aspartyl-seryl-prolyl-lysine | N2-(1-(N-(N-(N-(N2-Glycyl-L-arginyl)glycyl)-L-alpha-aspartyl)-L-seryl)-L-prolyl)-L-lysine | DTXSID20149506 | L-Lysine,glycy |
|---|---|
| Specifications & Purity | ≥99% |
| Biochemical and Physiological Mechanisms | GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorpt |
| Storage Temp | Desiccated,Store at -80°C |
| Shipped In |
Ice chest + Ice pads This product requires cold chain shipping. Ground and other economy services are not available. |
| Product Description |
GRGDSPK (EMD 56574) is a peptide incluing Arg-Gly-Asp (RGD). GRGDSPK (EMD 56574) is an competitive and reversible inhibitory peptide for inhibiting integrin-fibronectin binding. GRGDSPK is used to study the role of integrins in bone formation and resorption. In Vitro GRGDSPK (EMD 56574; RGD; 0.1-50 μM; for 4 days) inhibits mineralization in a dose-dependent manner as determined by measuring calcium content and 70 bonehnit area of tissue in parietal bones 18 days old isolated from pregnant Sprague-Dawley rats. GRGDSPK (10, 50 μM; for 4 days) dramatically alteres bone morphology, with a disruption of osteoblast and mineralized matrix organization. GRGDSPK (RGD; 250 μM), added to the medium, effectively blocks integrin-fibronectin binding and significantly increases the average size of wild-type cell aggregates. When GRGDSPK (250 μM) is added, wild-type mesendodermal progenitors exhibits strongly reduced adhesion forces and work, indicating that the detachment parameters recorded are specific for fibronectin and that integrins expressed in mesendodermal progenitors are involved. GRGDSPK (RGD-containing, 1.5 mM, 1.0 mM, and 0.5 mM) and RGD-mod-ified peptides impair the ability of sperm to fertilizebovine oocytes, illustrated by a reduction in cleavage in a dose-dependent manner. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid |
Taxonomy Tree
| Kingdom | Organic compounds |
|---|---|
| Superclass | Organic acids and derivatives |
| Class | Carboxylic acids and derivatives |
| Subclass | Amino acids, peptides, and analogues |
| Intermediate Tree Nodes | Peptides |
| Direct Parent | Oligopeptides |
| Alternative Parents | Aspartic acid and derivatives Proline and derivatives N-acyl-L-alpha-amino acids Alpha amino acid amides Pyrrolidinecarboxamides N-acylpyrrolidines Medium-chain fatty acids Amino fatty acids Hydroxy fatty acids Heterocyclic fatty acids N-acyl amines Dicarboxylic acids and derivatives Tertiary carboxylic acid amides Secondary carboxylic acid amides Amino acids Guanidines Propargyl-type 1,3-dipolar organic compounds Azacyclic compounds Carboximidamides Carboxylic acids Carbonyl compounds Primary alcohols Organopnictogen compounds Organic oxides Monoalkylamines Hydrocarbon derivatives |
| Molecular Framework | Aliphatic heteromonocyclic compounds |
| Substituents | Alpha-oligopeptide - Aspartic acid or derivatives - Proline or derivatives - N-acyl-l-alpha-amino acid - N-acyl-alpha-amino acid - N-acyl-alpha amino acid or derivatives - Alpha-amino acid amide - N-substituted-alpha-amino acid - Alpha-amino acid or derivatives - N-acylpyrrolidine - Pyrrolidine carboxylic acid or derivatives - Pyrrolidine-2-carboxamide - Medium-chain fatty acid - Amino fatty acid - Heterocyclic fatty acid - Hydroxy fatty acid - Dicarboxylic acid or derivatives - Fatty amide - N-acyl-amine - Fatty acyl - Fatty acid - Tertiary carboxylic acid amide - Pyrrolidine - Secondary carboxylic acid amide - Amino acid or derivatives - Carboxamide group - Guanidine - Amino acid - Propargyl-type 1,3-dipolar organic compound - Azacycle - Organic 1,3-dipolar compound - Carboxylic acid - Carboximidamide - Organoheterocyclic compound - Primary amine - Hydrocarbon derivative - Alcohol - Primary aliphatic amine - Organic nitrogen compound - Carbonyl group - Organic oxide - Organic oxygen compound - Amine - Organopnictogen compound - Organonitrogen compound - Organooxygen compound - Primary alcohol - Aliphatic heteromonocyclic compound |
| Description | This compound belongs to the class of organic compounds known as oligopeptides. These are organic compounds containing a sequence of between three and ten alpha-amino acids joined by peptide bonds. |
| External Descriptors | Not available |
|
|
|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| IUPAC Name | (2S)-6-amino-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[(2-aminoacetyl)amino]-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]pyrrolidine-2-carbonyl]amino]hexanoic acid |
|---|---|
| INCHI | InChI=1S/C28H49N11O11/c29-8-2-1-5-16(27(49)50)37-25(47)19-7-4-10-39(19)26(48)18(14-40)38-24(46)17(11-22(43)44)36-21(42)13-34-23(45)15(35-20(41)12-30)6-3-9-33-28(31)32/h15-19,40H,1-14,29-30H2,(H,34,45)(H,35,41)(H,36,42)(H,37,47)(H,38,46)(H,43,44)(H,49,50)(H4,31,32,33)/t15-,16-,17-,18-,19-/m0/s1 |
| InChIKey | ZRVZOBGMZWVJOS-VMXHOPILSA-N |
| Smiles | C1CC(N(C1)C(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)CNC(=O)C(CCCN=C(N)N)NC(=O)CN)C(=O)NC(CCCCN)C(=O)O |
| Isomeric SMILES | C1C[C@H](N(C1)C(=O)[C@H](CO)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)C(=O)N[C@@H](CCCCN)C(=O)O |
| Alternate CAS | 111119-28-9 |
| PubChem CID | 130667 |
| MeSH Entry Terms | Gly-Arg-Gly-Asp-Ser-Pro-Lys;glycyl- arginyl-glycyl-aspartyl-seryl-prolyl-lysine;GRGDSPK |
| Molecular Weight | 715.76 |
| Solubility | H2O Peptide Solubility and Storage Guidelines: 1. Calculate the length of the peptide. 2. Calculate the overall charge of the entire peptide according to the following table: Contents Assign value Acidic amino acid Asp (D), Glu (E), a |
|---|---|
| Molecular Weight | 715.800 g/mol |
| XLogP3 | -10.700 |
| Hydrogen Bond Donor Count | 12 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 23 |
| Exact Mass | 715.361 Da |
| Monoisotopic Mass | 715.361 Da |
| Topological Polar Surface Area | 377.000 Ų |
| Heavy Atom Count | 50 |
| Formal Charge | 0 |
| Complexity | 1250.000 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| The total count of all stereochemical bonds | 0 |
| Covalently-Bonded Unit Count | 1 |